→ Is This The End of Capitalism? (From Porter & Company)

Johnson & Johnson (NYSE:JNJ – Get Rating) – Cantor Fitzgerald increased their FY2023 earnings per share estimates for Johnson & Johnson in a research note issued on Wednesday, January 25th. Cantor Fitzgerald analyst L. Chen now expects that the company will post earnings of $10.45 per share for the year, up from their prior estimate of $9.49. The consensus estimate for Johnson & Johnson’s current full-year earnings is $10.51 per share.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, beating analysts’ consensus estimates of $2.22 by $0.13. The business11 of had revenue7 billion for the quarter, compared to the consensus estimate of $23.90 billion. Johnson & Johnson had a return on equity of 35.94% and a net margin of 18.90%. Johnson & Johnson’s revenue for the quarter was down 4.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.13 earnings per share.

JNJ has been the subject of a number of other research reports. Atlantic Securities boosted their price target on Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 25th. Morgan Stanley boosted their price objective on Johnson & Johnson from $176.00 to $180.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 25th. SVB Leerink cut their price objective on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research report on Friday, January 20th. Barclays assumed coverage on Johnson & Johnson in a research note on Monday, October 17th. They set an “equal weight” rating and a $175.00 price target on the stock. Finally, Citigroup boosted their price target on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research note on Monday, December 12th. Seven research analysts have rated the stock with a hold rat ing, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $182.75.

Johnson & Johnson Price Performance

JNJ opened at $168.23 on Monday. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The stock has a fifty day moving average price of $175.63 and a 200 day moving average price of $170.93. The stock has a market cap of $439.83 billion, a price-to-earnings ratio of 24.96, a PEG ratio of 2.89 and a beta of 0.56. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be issued a dividend of $1.13 per share. The ex-dividend date is Friday, February 17th. a $4.52 annualized dividend and a dividend yield of 2.69%. Johnson & Johnson’s dividend payout ratio is presently 67.06%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, VP Thibaut Mongon sold 35,246 shares of the business’s stock in a transaction on Friday, November 4th. The shares were sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the ice sale The president now owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. on Friday, November 4th. The shares were sold at an average price of $171.18, for a total value of $6,033,410.28. Following the transaction, the vice president now owns 40,133 shares in the company, valued at $6,869,966.94. The transaction was filed with the SEC, which is available through this link. Also, EVP Kathryn E. Wengel sold 16,410 shares of the company’s stock in a transaction dated Wednesday, November 9th. The shares were so ld at an average price of $173.42, for a total transaction of $2,845,822.20. Following the transaction, the executive vice president now owns 71,311 shares in the company, valued at approximately $12,366,753.62. days, insiders have sold 233,611 shares of company stock valued at $40,960,735. 0.35% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Johnson & Johnson

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Morton Brown Family Wealth LLC grew its position in Johnson & Johnson by 78.0% in the 2nd quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’ stock worth $32,000 after purchasing an additional 78 shares in the last quarter. Glassy Mountain Advisors Inc. bought a new stake in Johnson & Johnson in the 4th quarter worth about $35,000. Goodman Advisory Group LLC bought a new stake in Johnson & Johnson in the 2nd quarter worth about $39,000. Retirement Financial Solutions LLC bought a new stake in Johnson & Johnson in the 4th quarter worth about $40,000. Finally, TD Capital Management LLC bought a new stake in Johnson & Johnson in the 3rd quarter worth about $46.70 the stock is owned by institutional investors.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or out comments about this story contact@marketbeat.com.

Before you consider Johnson & Johnson, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before market the broader on… and Johnson & Johnson wasn’t on the list.

While Johnson & Johnson currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here